ArticleCancer management and research2019

Is ramucirumab and paclitaxel therapy beneficial for second-line treatment of metastatic gastric or junctional adenocarcinoma for patients with ascites? Analysis of RAINBOW phase 3 trial data.

Kei Muro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.